Publications by authors named "M Alrouji"

Article Synopsis
  • Epigenetic processes, particularly histone modification by HDACs, are crucial in cancer development, making HDACs important targets for cancer therapies.
  • The challenge with most HDAC inhibitors is their non-selective nature and drug resistance, prompting a search for more effective and isoform-selective options.
  • Alectinib has been identified through virtual screening as a potential HDAC1 inhibitor with better efficiency and stability, suggesting its promise for therapy in HDAC1-related cancers, pending further validation.
View Article and Find Full Text PDF

Alzheimer's disease (AD) is a neurodegenerative disease characterized by cognitive impairment and memory deficit. Even with extensive research and studies, presently, there is no effective treatment for the management of AD. Besides, most of drugs used in the treatment of AD did not avert the AD neuropathology, and the disease still in a progressive status.

View Article and Find Full Text PDF

Alzheimer's disease (AD) is characterized by the aggregation of amyloid β (Aβ) peptides and the formation of plaques in the brain, primarily derived from the proteolytic degradation of amyloid precursor protein (APP). Cathepsin B (CatB) is a cysteine protease that plays a pivotal role in this process, making it a potential target for the development of anti-Alzheimer's therapies. Apart from AD, CatB is implicated in various physiological and pathological processes, including cancer.

View Article and Find Full Text PDF

In recent times, neurodegenerative diseases (NDs), such as Alzheimer's disease (AD), Parkinson's disease (PD) and others, represent a major global health challenge with increasing prevalence and significant socio-economic impact. These diseases, characterized by progressive neuronal loss, currently lack effective therapies. Phytochemicals offer promising therapeutic potential due to their diverse bioactive properties.

View Article and Find Full Text PDF

The metabolic syndrome (MetS) is a clustering of abdominal obesity, hypertension, hyperglycaemia, hypertriglyceridemia and low high-density lipoprotein (HDL) level. MetS development is affected by endocrine hormones such as prolactin (PRL) hormone which induce insulin resistance and central obesity because PRL is implicated in the pathogenesis of MetS. Pituitary PRL controls mammary gland, however extra-pituitary PRL is highly intricate in the regulation of adipose tissue function.

View Article and Find Full Text PDF